- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07780032
Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Restless Legs Syndrome (RLS) is a chronic neurological disorder characterized by an urge to move the legs that disrupts sleep and quality of life. Current medical therapies often lose effectiveness over time or are associated with significant side effects. Preliminary case reports suggest that spinal cord stimulation (SCS) may improve RLS symptoms.
This single-arm feasibility study will enroll up to 15 adults with severe, treatment-refractory primary RLS. Participants will undergo baseline clinical, neuropsychological, and electrophysiological assessments followed by implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System. Follow-up evaluations will occur through 24 months post-activation. Primary outcomes focus on device and procedure safety. Secondary outcomes evaluate changes in RLS severity, patient-reported outcomes, neurophysiological biomarkers, and device utilization.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Chris Gonzalez
- Telefonnummer: 2059964318
- E-post: clgonzalez@uabmc.edu
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- UAB Hospital
-
Kontakt:
- Chris Gonzalez
- Telefonnummer: 2059964318
- E-post: clgonzalez@uabmc.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Age >18 years and older.
- Received a medical diagnosis of RLS via first screening with Cambridge Hopkins- RLS questionnaire and confirmed via Hopkins-Hening Diagnostic questionnaire.
- IRLS Scale score ≥ 21 (classified as severe) and received a determination of treatment refractory RLS or inadequate response to standard medical treatment for RLS by a sleep medicine physician.
- RLS symptoms occur ≥ 3 nights per week.
- Willing and able to comply with study procedures.
- Able to provide informed consent.
Exclusion Criteria:
- Age <18 years.
- Neuropathic pain, other than RLS on DN4 questionnaire.
- Any mental or physical limitation that would prevent completing and of the study protocols.
- Active medical implant in the body (i.e., pacemaker).
- History of prior SCS trial or implantation.
- Currently using another device to treat RLS.
- Unable or unwilling to comply with study protocols.
- Other medical conditions that would put the subject at risk as determined by the investigators.
- Pregnant, breastfeeding, or trying to become pregnant.
- Currently participating or plans to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigators, affect RLS.
- Ferritin < 50 ng/mL (excludes iron deficiency).
- HgA1C > 7.5 (excludes unstable diabetes melilitus)
- One or more of the following diagnoses: spinal cord injury or prior spinal surgery, severe peripheral neuropathy, severe psychiatric or cognitive disorder that may interfere with study participation, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e., Parkinson's disease), deep vein thrombosis, multiple sclerosis, known or suspected allergy to SCS materials.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: SCS Implant
|
Implantation of the FDA-approved Saluda Medical Evoke® Spinal Cord Stimulation System with Smartloop® Technology.
Two percutaneous epidural leads will be implanted in the thoracic spine (T7-T10 region) and programmed to provide chronic spinal cord stimulation for treatment of severe RLS symptoms.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Safety and Adverse Events
Tidsram: Baseline through 24 months
|
Frequency, severity, and relationship of device-, stimulation-, and procedure-related adverse events.
|
Baseline through 24 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in International Restless Legs Syndrome Scale (IRLS)
Tidsram: Baseline through 24 months
|
The IRLS is a validated 10-item patient-reported measure of Restless Legs Syndrome severity.
Scores range from 0 to 40, with higher scores indicating worse symptom severity.
A decrease in score from baseline indicates improvement.
|
Baseline through 24 months
|
|
Clinician Global Impression Improvement Scale (CGI-I)
Tidsram: Baseline through 24 months
|
Baseline through 24 months
|
|
|
Patient Global Impression of Improvement (PGI-I)
Tidsram: Baseline through 24 months
|
The PGI-I is a patient-reported global rating of change in symptoms and overall condition following treatment.
Scores range from 1 to 7, where 1 = Very much improved and 7 = Very much worse.
Lower scores represent a better outcome and greater perceived improvement.
|
Baseline through 24 months
|
|
Suggested Immobilization Test (SIT)
Tidsram: Baseline through 24 months
|
Baseline through 24 months
|
|
|
PROMIS Sleep, Pain, Anxiety, Depression, Cognition, and Health Measures
Tidsram: Baseline through 24 months
|
Baseline through 24 months
|
|
|
Changes in Neurophysiological Measures of Spinal Cord Stimulation Response
Tidsram: Baseline through 24 months
|
Changes in H-reflexes, somatosensory evoked potentials (SSEPs), EEG measures, and device-recorded ECAPs.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Sleep
Tidsram: Baseline through 24 months
|
Questionnaire assessing perceived sleep quality and difficulty falling asleep during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater sleep disturbance and a worse outcome.
The T-score range is approximately 20 to 80
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Pain
Tidsram: Baseline through 24 months
|
Questionnaire assessing the impact of pain on daily activities and sleep during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater pain interference and a worse outcome.
The T-score range is approximately 30 to 80
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Anxiety
Tidsram: Baseline through 24 months
|
Questionnaire assessing fear, anxious mood, and anxiety-related symptoms during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater anxiety and a worse outcome.
The T-score range is approximately 40 to 85.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Depression
Tidsram: Baseline through 24 months
|
Questionnaire assessing depressive symptoms, negative mood, and diminished self-worth during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater depressive symptom burden and a worse outcome.
The T-score range is approximately 40 to 85.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Cognition
Tidsram: Baseline through 24 months
|
Questionnaire assessing perceived cognitive abilities including memory, concentration, and mental acuity.
Responses are converted to PROMIS standardized T-scores .
Higher scores indicate better cognitive functioning and a better outcome.
The T-score range is approximately 20 to 80.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Mental health battery
Tidsram: Baseline through 24 months
|
Assesses overall mental health.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate better overall health status and a better outcome.
T-score range is approximately 20 to 80
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Physical Health Battery
Tidsram: Baseline through 24 months
|
Assesses Overall Physical Health.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate better overall health status and a better outcome.
T-score range is approximately 20 to 80
|
Baseline through 24 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Marshall Holland, MD, University of Alabama at Birmingham
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IRB-300013464
- 1UG3NS145980-01 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .